These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33942286)

  • 1. Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.
    Murrell DF; Patsatsi A; Stavropoulos P; Baum S; Zeeli T; Kern JS; Roussaki-Schulze AV; Sinclair R; Bassukas ID; Thomas D; Neale A; Arora P; Caux F; Werth VP; Gourlay SG; Joly P;
    Br J Dermatol; 2021 Oct; 185(4):745-755. PubMed ID: 33942286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study.
    Murrell DF; Caux F; Patsatsi A; Hagino O; Rudnicka L; Vassileva S; Uzun S; Ye J; Yen K; Arora P; Gourlay SG; Joly P; Werth VP
    J Invest Dermatol; 2024 Aug; 144(8):1762-1771.e6. PubMed ID: 38493933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease.
    Langrish CL; Bradshaw JM; Francesco MR; Owens TD; Xing Y; Shu J; LaStant J; Bisconte A; Outerbridge C; White SD; Hill RJ; Brameld KA; Goldstein DM; Nunn PA
    J Immunol; 2021 Apr; 206(7):1454-1468. PubMed ID: 33674445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus.
    Patsatsi A; Murrell DF
    Front Med (Lausanne); 2021; 8():708071. PubMed ID: 34447768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
    Kuter DJ; Efraim M; Mayer J; Trněný M; McDonald V; Bird R; Regenbogen T; Garg M; Kaplan Z; Tzvetkov N; Choi PY; Jansen AJG; Kostal M; Baker R; Gumulec J; Lee EJ; Cunningham I; Goncalves I; Warner M; Boccia R; Gernsheimer T; Ghanima W; Bandman O; Burns R; Neale A; Thomas D; Arora P; Zheng B; Cooper N
    N Engl J Med; 2022 Apr; 386(15):1421-1431. PubMed ID: 35417637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).
    Owens TD; Brameld KA; Verner EJ; Ton T; Li X; Zhu J; Masjedizadeh MR; Bradshaw JM; Hill RJ; Tam D; Bisconte A; Kim EO; Francesco M; Xing Y; Shu J; Karr D; LaStant J; Finkle D; Loewenstein N; Haberstock-Debic H; Taylor MJ; Nunn P; Langrish CL; Goldstein DM
    J Med Chem; 2022 Apr; 65(7):5300-5316. PubMed ID: 35302767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial.
    Goebeler M; Bata-Csörgő Z; De Simone C; Didona B; Remenyik E; Reznichenko N; Stoevesandt J; Ward ES; Parys W; de Haard H; Dupuy P; Verheesen P; Schmidt E; Joly P;
    Br J Dermatol; 2022 Mar; 186(3):429-439. PubMed ID: 34608631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
    Chen DM; Odueyungbo A; Csinady E; Gearhart L; Lehane P; Cheu M; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Musette P; Joly P;
    Br J Dermatol; 2020 May; 182(5):1111-1119. PubMed ID: 31487383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus.
    Yamagami J; Ujiie H; Aoyama Y; Ishii N; Tateishi C; Ishiko A; Ichijima T; Hagihara S; Hashimoto K; Amagai M
    J Dermatol Sci; 2021 Sep; 103(3):135-142. PubMed ID: 34376340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus.
    Goodale EC; Varjonen KE; Outerbridge CA; Bizikova P; Borjesson D; Murrell DF; Bisconte A; Francesco M; Hill RJ; Masjedizadeh M; Nunn P; Gourlay SG; White SD
    Vet Dermatol; 2020 Aug; 31(4):291-e71. PubMed ID: 31899567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus.
    Goodale EC; White SD; Bizikova P; Borjesson D; Murrell DF; Bisconte A; Francesco M; Hill RJ; Masjedizadeh M; Nunn P; Gourlay SG; Jordan TJM; Emery CB; Outerbridge CA
    Vet Dermatol; 2020 Oct; 31(5):410-e110. PubMed ID: 32803903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
    Mendes-Bastos P; Brasileiro A; Kolkhir P; Frischbutter S; Scheffel J; Moñino-Romero S; Maurer M
    Allergy; 2022 Aug; 77(8):2355-2366. PubMed ID: 35175630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
    Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
    Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects.
    Ucpinar S; Darpo B; Neale A; Nunn P; Shu J; Chu KA; Kavanagh M; Xue H; Phiasivongsa P; Thomas D; Smith PF
    Clin Transl Sci; 2022 Jun; 15(6):1507-1518. PubMed ID: 35301810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
    Joly P; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Vermeulin T; Benichou J; Musette P;
    Lancet; 2017 May; 389(10083):2031-2040. PubMed ID: 28342637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rilzabrutinib
    Kuter DJ; Bussel JB; Ghanima W; Cooper N; Gernsheimer T; Lambert MP; Liebman HA; Tarantino MD; Lee M; Guo H; Daak A
    Ther Adv Hematol; 2023; 14():20406207231205431. PubMed ID: 37869360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first-line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial.
    Hébert V; Vermeulin T; Tanguy L; Tedbirt B; Mignard C; Bénichou J; Joly P
    Br J Dermatol; 2020 Jul; 183(1):121-127. PubMed ID: 31657454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors.
    Naik PP
    J Transl Autoimmun; 2022; 5():100156. PubMed ID: 35493759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
    España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
    Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.